Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

European Journal of Cancer(2023)10.1016/j.ejca.2023.01.031Source: DataRank Database

OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer is a research paper published in European Journal of Cancer (2023). On theSindex it has a DataRank of 0. It has been cited 113 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access113 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Topics (16)IDs (PubMed, PMC)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (13)

Seock‐Ah Im ORCID,Elżbieta Senkus ORCID,Binghe Xu ORCID,Susan M. Domchek ORCID,Norikazu Masuda ORCID

Live enrichment

PubMed:36893711 PMC:PMC10585240

NCI NIH HHS

Grant: P30 CA008748

AstraZeneca PLC

NCI

MeSH Terms

HumansBreast NeoplasmsPiperazinesPhthalazinesFollow-Up StudiesGerm-Line MutationGenes, BRCA1Genes, BRCA2PhysiciansFemaleErb-b2 Receptor Tyrosine Kinases

Keywords

Breast cancerOverall SurvivalOlaparibParp InhibitorGermline Brca Mutation

OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

FAIR Checklist

Authors (13)

Funding (3 grants)

Topics

Annotations (Europe PMC)